Table 2– Adenosine monophosphate (AMP) provocative concentration causing a 20% fall in forced expiratory volume in 1 s (PC₂₀) for the different particle sizes, measuremed at baseline and after treatment with ciclesonide or fluticasone

	All subjects			Subjects with baseline PC₂₀ <640 mg·mL⁻¹
	Ciclesonide	Fluticasone	p-value	Ciclesonide	Fluticasone	p-value
Subjects n	19	18		11	12
Baseline PC₂₀ DD
Standard-particle AMP	4.2±2.8	3.5±2.1	0.41
Large-particle AMP	4.9±3.3	3.8±3.2	0.30	3.7±2.6	3.0±2.4	0.44
Small-particle AMP	6.8±3.6	6.6±2.7	0.87	4.9±3.7	5.2±2.1	0.81
Post-treatment PC₂₀ DD
Large-particle AMP	4.8±2.7	4.5±2.3	0.77	4.5±2.3^#	4.3±2.4^¶	0.89
Small-particle AMP	7.4±2.0	6.7±2.8	0.42	6.6±2.0^¶	6.0±2.7^#	0.53

Data are presented as mean±sd, unless otherwise stated. Values are ²log PC₂₀ values. Between-group differences were tested with t-test. The 23 subjects at the right part of the table are those subjects who reach a PC₂₀ <640 mg·mL⁻¹ with the the small- and large-particle AMP protocol at baseline. DD: doubling dose. ^# p = 0.17 within group;^¶: p = 0.03 within group.